MedTrace Logo

Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy

NCT04339634 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12873

Last updated 2023-01-31

No results posted yet for this study

Summary

This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in elderly patients infected with COVID-19.

Conditions

  • COVID
  • Drug Effect
  • Drug Interaction
  • Adverse Drug Event

Interventions

OTHER

Simulation of Repurposed Drugs for COVID-19

This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.

Sponsors & Collaborators

  • Tabula Rasa HealthCare

    lead INDUSTRY

Principal Investigators

  • Veronique Michaud, PhD · Tabula Rasa HealthCare

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-02
Primary Completion
2023-01-30
Completion
2023-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04339634 on ClinicalTrials.gov